1
|
Brachtl G, Piñón Hofbauer J, Greil R and
Hartmann TN: The pathogenic relevance of the prognostic markers
CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol.
93:361–374. 2014.PubMed/NCBI View Article : Google Scholar
|
2
|
Zenz T, Kröber A, Scherer K, Häbe S,
Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwänen C, et
al: Monoallelic TP53 inactivation is associated with poor prognosis
in chronic lymphocytic leukemia: Results from a detailed genetic
characterization with long-term follow-up. Blood. 112:3322–3329.
2008.PubMed/NCBI View Article : Google Scholar
|
3
|
Bulian P, Shanafelt TD, Fegan C, Zucchetto
A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA,
et al: CD49d is the strongest flow cytometry-based predictor of
overall survival in chronic lymphocytic leukemia. J Clin Oncol.
32:897–904. 2014.PubMed/NCBI View Article : Google Scholar
|
4
|
Zucchetto A, Caldana C, Benedetti D,
Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M,
D'Arena G, et al: CD49d is overexpressed by trisomy 12 chronic
lymphocytic leukemia cells: Evidence for a methylation-dependent
regulation mechanism. Blood. 122:3317–3321. 2013.PubMed/NCBI View Article : Google Scholar
|
5
|
Zucchetto A, Vaisitti T, Benedetti D,
Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe
MI, Gorgone A, et al: The CD49d/CD29 complex is physically and
functionally associated with CD38 in B-cell chronic lymphocytic
leukemia cells. Leukemia. 26:1301–1312. 2012.PubMed/NCBI View Article : Google Scholar
|
6
|
Uzay A, Toptas T, Kaygusuz I,
Ekşioğlu-Demiralp E, Tuglular TF and Bayık M: The prognostic value
of CD49d expression in Turkish patients with chronic lymphocytic
leukemia. Turk J Hematol. 29:354–360. 2012.
|
7
|
Mertens D and Stilgenbauer S: Prognostic
and predictive factors in patients with chronic lymphocytic
leukemia: Relevant in the era of novel treatment approaches? J Clin
Oncol. 32:869–872. 2014.PubMed/NCBI View Article : Google Scholar
|
8
|
Gattei V, Bulian P, Del Principe M,
Zucchetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano
F, Rossi FM, et al: Relevance of CD49d protein expression as
overall survival and progressive disease prognosticator in chronic
lymphocytic leukemia. Blood. 111:865–873. 2008.PubMed/NCBI View Article : Google Scholar
|
9
|
Jakšić B, Pejša V, Ostojić-Kolonić S,
Kardum-Skelin I, Bašić-Kinda S, Coha B, Gverić-Krečak V, Vrhovac R,
Jakšić O, Aurer I, et al: Guidelines for diagnosis and treatment of
chronic lymphocytic leukemia krohem B-Cll 2017. Acta Clin Croat.
57:190–215. 2018.PubMed/NCBI View Article : Google Scholar
|
10
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA and Stein H (eds): World Health Organization
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
4th edition, Volume 2. IARC Press, Lyon, France, 2008.
|
11
|
Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M,
Montserrat E, Chiorazzi N, et al: iwCLL guidelines for diagnosis,
indications for treatment, response assessment, and supportive
management of CLL. Blood. 131:2745–2760. 2018.PubMed/NCBI View Article : Google Scholar
|
12
|
Chen YH, Peterson LC, Dittmann D, Evens A,
Rosen S, Khoong A, Shankey TV, Forman M, Gupta R and Goolsby CL:
Comparative analysis of flow cytometric techniques in assessment of
ZAP-70 expression in relation to IgVH mutational status in chronic
lymphocytic leukemia. Am J Clin Pathol. 127:182–119.
2007.PubMed/NCBI View Article : Google Scholar
|
13
|
Dewald GW, Brockman SR, Paternoster SF,
Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC,
Hanson CA, et al: Chromosome anomalies detected by interphase
fluorescence in situ hybridization: Correlation with significant
biological features of B-cell chronic lymphocytic leukaemia. Br J
Haematol. 121:287–295. 2003.PubMed/NCBI View Article : Google Scholar
|
14
|
Chan YH: Biostatistics 102: Quantitative
data-parametric and non-parametric tests. Singapore Med J.
44:391–396. 2003.PubMed/NCBI
|
15
|
Chan YH: Biostatistics 103: Qualitative
data-tests of independence. Singapore Med J. 44:498–503.
2003.PubMed/NCBI
|
16
|
Popova V, Blazheva S, Lukanov T, Naneva S
and Tzvetkov N: Study of the immunological markers CD49d and CD38
in early-stage B-Cll patients. J IMAB. 24:1883–1886. 2018.
|
17
|
Saka B, Aktan M, Sami U, Oner D, Sanem O
and Dinçol G: Prognostic importance of soluble CD23 in B-cell
chronic lymphocytic leukemia. Clin Lab Haematol. 28:30–35.
2006.PubMed/NCBI View Article : Google Scholar
|
18
|
Strati P, Parikh SA, Chaffee KG, Achenbach
SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE and
Shanafelt TD: CD49d associates with nodal presentation and
subsequent development of lymphadenopathy in patients with chronic
lymphocytic leukaemia. Br J Haematol. 178:99–105. 2017.PubMed/NCBI View Article : Google Scholar
|
19
|
Baumann T, Delgado J, Santacruz R,
Martínez-Trillos A, Rozman M, Aymerich M, López C, Costa D, Carrió
A, Villamor N and Montserrat E: CD49d (ITGA4) expression is a
predictor of time to first treatment in patients with chronic
lymphocytic leukaemia and mutated IGHV status. Br J Haematol.
172:48–55. 2016.PubMed/NCBI View Article : Google Scholar
|
20
|
Fiorcari S, Benatti S, Zucchetto A,
Zucchini P, Gattei V, Luppi M, Marasca R and Maffei R:
Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia
patients is mediated by IRF4 through induction of IKAROS. Leukemia.
33:1278–1302. 2019.PubMed/NCBI View Article : Google Scholar
|
21
|
Tissino E, Pozzo F, Benedetti D, Caldana
C, Bittolo T, Rossi FM, Bomben R, Nanni P, Chivilò H, Cattarossi I,
et al: CD49d promotes disease progression in chronic lymphocytic
leukemia: New insights from CD49d bimodal expression. Blood.
135:1244–1254. 2020.PubMed/NCBI View Article : Google Scholar
|
22
|
Heintel D, Schwarzinger I,
Chizzali-Bonfadin C, Thalhammer R, Schwarzmeier J, Fritzer-Szekeres
M, Weltermann A, Simonitsch I, Lechner K and Jaeger U: Association
of CD38 antigen expression with other prognostic parameters in
early stages of chronic lymphocytic leukemia. Leuk Lymphoma.
42:1315–1321. 2001.PubMed/NCBI View Article : Google Scholar
|
23
|
Wierda WG, O'Brien S, Wang X, Faderl S,
Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C,
et al: Prognostic nomogram and index for overall survival in
previously untreated patients with chronic lymphocytic leukemia.
Blood. 109:4679–4685. 2007.PubMed/NCBI View Article : Google Scholar
|
24
|
Rossi D, Rasi S, Spina V, Bruscaggin A,
Monti S, Ciardullo C, Deambrogi C, Khiabanian H, Serra R, Bertoni
F, et al: Integrated mutational and cytogenetic analysis identifies
new prognostic subgroups in chronic lymphocytic leukemia. Blood.
121:1403–1412. 2013.PubMed/NCBI View Article : Google Scholar
|
25
|
Pflug N, Bahlo J, Shanafelt TD, Eichhorst
BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer
S, et al: Development of a comprehensive prognostic index for
patients with chronic lymphocytic leukemia. Blood. 124:49–62.
2014.PubMed/NCBI View Article : Google Scholar
|
26
|
Benedetti D, Tissino E, Pozzo F, Bittolo
T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi
FM, et al: NOTCH1 mutations are associated with high CD49d
expression in chronic lymphocytic leukemia: Link between the NOTCH1
and the NF-κB pathways. Leukemia. 32:654–662. 2018.PubMed/NCBI View Article : Google Scholar
|
27
|
Pozzo F, Bittolo T, Vendramini E, Bomben
R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G,
et al: NOTCH1-mutated chronic lymphocytic leukemia cells are
characterized by a MYC-related overexpression of nucleophosmin 1
and ribosome-associated components. Leukemia. 31:2407–2415.
2017.PubMed/NCBI View Article : Google Scholar
|
28
|
Cohen JA, Bomben R, Pozzo F, Tissino E,
Härzschel A, Hartmann TN, Zucchetto A and Gattei V: An updated
perspective on current prognostic and predictive biomarkers in
chronic lymphocytic leukemia in the context of chemoimmunotherapy
and novel targeted therapy. Cancers (Basel). 12(894)2020.PubMed/NCBI View Article : Google Scholar
|